<- Go Home
Panacos Pharmaceuticals, Inc.
Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company’s discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition. The company was founded in 1999 and is headquartered in Watertown, Massachusetts.
Market Cap
$53.00
Volume
427.7K
Cash and Equivalents
$21.4M
EBITDA
-$33.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$99.0K
Profit Margin
100.00%
52 Week High
$0.01
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
0.00
Price / Earnings
-0.00
Price / Tangible Book Value
0.00
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$34.2M
Return on Equity
168.83%
Return on Assets
-52.62
Cash and Short Term Investments
$26.9M
Debt
$18.2M
Equity
$5.3M
Revenue
$99.0K
Unlevered FCF
-$15.8M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium